Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations, today announced it will be presenting its abstract ...

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough ...

Rates of menopause hormone therapy significantly differed by racial group, a retrospective cohort study found. Non-Hispanic ...

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

Erasca's share price nosedived 53% after a patient died in its Phase I trial of ERAS-0015, and rival Revolution Medicine ...

Researchers have reported biologic abnormalities in long COVID, challenging the view that symptoms are primarily psychosomatic.

Retia Medical today announced the first public presentation of results from its non-invasive cardiac output algorithm, which ...

Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung ...

Kymera Therapeutics (NASDAQ:KYMR) highlighted progress across its clinical-stage pipeline and provided a financial update ...

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

Results presented here showed women on hormonal contraception before ACL surgery were more likely to experience complications ...

The patient was diagnosed with bronchial casts made from particulate matter from forest fire smoke. When the lungs get ...